Supramolecular Pretargeting Lipid Nanoparticles Based on Host–Guest Recognition Potentiate Cancer Immunotherapy by Reprogramming Tumor Microenvironment
Angewandte Chemie International Edition · 2026
DOI: 10.1002/anie.9573178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Jinqun Gan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, P.R. China. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy, Nanoparticles, Lipids. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Key R&D Program of China, Beijing Municipal Science & Technology Commission, the Tsinghua University Dushi Program.
Abstract (Originalsprache)
Lipid nanoparticles (LNPs) have emerged as a promising platform for gene/drug delivery in cancer therapy, however their nonspecific biodistribution and extensive hepatosplenic sequestration result in insufficient intratumoral accumulation, thereby undermining the therapeutic efficacy. Here, we establish a sequential pretargeting strategy exploiting the high‐affinity host–guest recognition between adamantane (ADA) and cucurbit[7]uril (CB[7]) to enhance tumor enrichment. Preadministered ADA‐conjugated anti‐PD‐L1 antibody (ADA‐αPD‐L1) primes tumors for efficient capture of subsequently infused CB[7]‐functionalized LNPs (CN‐LNPs), improving intratumoral retention and cellular uptake. To concurrently address the immunosuppressive tumor microenvironment, NLG919 is covalently incorporated into the ionizable lipid of CN‐LNPs to inhibit IDO‐mediated tryptophan catabolism, effectively attenuating regulatory T cell activity while preserving the pretargeting functionality of the nanocarrier. CN‐LNPs are employed as a delivery platform to encapsulate a circular RNA encoding IL‐2‐Fc fusion protein (CN‐LNPs@cRNA IL‐2F ), enabling intratumoral cytokine production to potentiate antitumor immunity. CN‐LNPs@cRNA IL‐2F elicit robust antitumor immunity to suppress tumor growth and extend survival, establishing a versatile platform that overcomes the intratumoral delivery limitations commonly associated with conventional LNPs system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, P.R. China.
- CAS Key Laboratory of Standardization and Measurement for Nanotechnology, National Center for Nanoscience and Technology, Beijing, P.R. China.
- State Key Laboratory of Natural Medicines, School of Biopharmacy, School of Elite Biomedical Engineers, China Pharmaceutical University, Nanjing, P.R. China.
ORCID-Profile: Jinqun Gan, Shizhen Cui, Ling Zhu, Guocan Yu
Förderung
- National Key R&D Program of China
- Beijing Municipal Science & Technology Commission
- the Tsinghua University Dushi Program
- the Jiangsu Provincial Major Science and Technology Special Fund
- National Key Research and Development Program of China
Zitieren
APA
Gan, J., Wang, Y., Li, M., Cui, S., Zhu, L., Yu, X., Liu, Z., & Yu, G. (2026). Supramolecular Pretargeting Lipid Nanoparticles Based on Host–Guest Recognition Potentiate Cancer Immunotherapy by Reprogramming Tumor Microenvironment. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.9573178
Vancouver
Gan J, Wang Y, Li M, Cui S, Zhu L, Yu X, et al. Supramolecular Pretargeting Lipid Nanoparticles Based on Host–Guest Recognition Potentiate Cancer Immunotherapy by Reprogramming Tumor Microenvironment. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.9573178
BibTeX
@article{Gan2026,
author = {Gan, Jinqun and Wang, Yangfan and Li, Mengyao and Cui, Shizhen and Zhu, Ling and Yu, Xinyang and Liu, Zhida and Yu, Guocan},
title = {Supramolecular Pretargeting Lipid Nanoparticles Based on Host–Guest Recognition Potentiate Cancer Immunotherapy by Reprogramming Tumor Microenvironment},
journal = {Angewandte Chemie International Edition},
year = {2026},
doi = {10.1002/anie.9573178}
}
EUVIMED